Predictive value of XRCC1 Arg399Gln gene polymorphism in the adverse events and prognosis of postoperative SOX chemotherapy for advanced gastric cancer
10.3760/cma.j.cn115455-20221006-00852
- VernacularTitle:X射线修复交叉互补1 Arg399Gln基因多态性对胃癌术后SOX化疗不良反应及预后的预测价值
- Author:
Linhai ZHENG
1
;
Jun QIAN
;
Shaoliang HAN
Author Information
1. 温州医科大学附属衢州医院（衢州市人民医院）胃肠外科，衢州 324000
- Keywords:
Stomach neoplasms;
Gene;
X-ray repair cross complementing 1;
Polymorphism;
Oxaliplatin
- From:
Chinese Journal of Postgraduates of Medicine
2023;46(10):865-870
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the predictive value of XRCC1 Arg399Gln gene polymorphism in the adverse events and prognosis of SOX chemotherapy for advanced gastric cancer after D2 resection.Methods:A total of 62 patients with advanced gastric cancer receiving Sox chemotherapy after D2 resection from January 2015 to April 2018 in Quzhou People′s Hospital were included and the baseline characteristics were collected retrospectively. Postoperative pathological specimens were used for genotyping of XRCC1 Arg399Gln gene variation. To analyze the relationship between the polymorphism of XRCC1 Arg399Gln in patients and the clinicopathological features and the occurrence of adverse chemotherapy reactions. Also, to evaluate the disease-free survival (DFS) and overall survival(OS) of patients in the different genotypes. Cox regression analysis was used to screen for prognostic risk factors.Results:The genotype distribution of XRCC1 Arg399Gln locus in 62 patients with gastric cancer was G/G in 35 cases (56.45%), G/A in 21 cases (33.87%) and A/A in 6 cases (9.68%). And the distribution frequencies of the three genotypes were in accordance with the hardy-weinberg equilibrium( P = 0.295). G/A and A/A genotypes were merged in the subsequent analysis. Comparison of baseline characteristics between the G/G genotype and G/A+A/A genotype showed no statistically significant differences (all P>0.05). Different genotypes had no significant differences in the adverse reactions of Sox chemotherapy after advanced gastric cancer surgery (all P>0.05). The median DFS of the G/G genotype was 45 months (95% CI 41.73 - 48.28), which was higher than G/A+A/A genotype 38 months (95% CI 35.71 - 40.29)( P = 0.047). Univariate Cox regression analysis showed that the polymorphism of XRCC1 Arg399Gln was risk factor for tumor recurrence in patients with advanced gastric cancer who received SOX chemotherapy after surgery ( RR = 2.178, 95% CI 1.078 - 4.402, P = 0.030). Multivariate Cox regression analysis showed that the polymorphism of XRCC1 Arg399Gln was independent risk factor for tumor recurrence in patients with advanced gastric cancer who received SOX chemotherapy after surgery ( RR = 2.581, 95% CI 1.242 - 5.363, P = 0.011). The median OS of G/G genotype and G/A+A/A genotype were 60 months (95% CI 57.81 - 62.19) and 55 months (95% CI 49.62 - 60.38). There was no significant difference in OS between G/G genotype and G/A+A/A genotype ( P = 0.202). Univariate regression analysis showed that the polymorphism of XRCC1 Arg399Gln wasn′t risk factor for death in patients with advanced gastric cancer who received SOX chemotherapy after surgery ( RR = 1.702, 95% CI 0.744 - 3.896, P = 0.208). Conclusions:The XRCC1 Arg399Gln gene polymorphism has no correlation with the adverse reactions of SOX chemotherapy after D 2 resection for advanced gastric cancer. But, the XRCC1 Arg399Gln G/G type is closely associated with the prognosis of patients, it has predictive value for better DFS.
